Obesity as the core of the metabolic syndrome and the management of coronary heart disease

References

• World Health Organization. The World Health Report 2001 annex Table 2. Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2000. Available from: URL: http://www.who.int/whr/2001/main/en/annex/annex2.htm [Accessed 24 October 2003]
   Google Scholar
• Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–504
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9
   Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Airforce/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22
   Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601–10
   Google Scholar
• Japan Atherosclerosis Society. Available from: URL: http://jas.umin.ac.jp [Accessed 3 November 2003]
   Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;329: 229–34
   Google Scholar
• Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713–24
   PubMed Web of Science ®Google Scholar
• Saito Y, Shirai K, Sasaki N, et al. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study. J Atheroscler Thromb 2002;9:99–108
   PubMedGoogle Scholar
• Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514–20
   PubMed Web of Science ®Google Scholar
• Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473–86
   PubMed Web of Science ®Google Scholar
• Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83:25F–29F
   Google Scholar
• Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000;152:908–11
   PubMed Web of Science ®Google Scholar
• Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897–907
   PubMed Web of Science ®Google Scholar
• Isomaa B, Lahti K, Almgren P, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683–9
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–9
   Google Scholar
• Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473–81
   PubMed Web of Science ®Google Scholar
• International Union of Nutritional Sciences. The global challenge of obesity and the International Obesity Task Force. Available from: URL: http://www.iuns.org/features/obesity/obesity.htm [Accessed 30 October 2003]
   Google Scholar
• World Health Organization Health Topics. Nutrition. Available from: URL: http://www.who.int/nut/obs.htm [Accessed 24 October 2003]
   Google Scholar
• World Health Organization. Obesity: preventing and managing the global epidemic. WHO obesity technical report series 894. Geneva, Switzerland: World Health Organization; 2000
   Google Scholar
• James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;9\(Suppl 4):228S–233S
   Google Scholar
• Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998;22:39–47
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Prevalence of overweight and obesity among adults: United States, 1999–2000. Available from: URL: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99.htm [Accessed 24 October 2003]
   Google Scholar
• International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment; 2000. Available from: URL: http://www.iotf.org [Accessed 24 October 2003]
   Google Scholar
• Yoshiike N, Seino F, Tajima S, et al. Twenty-year changes in the prevalence of overweight in Japanese adults: the National Nutrition Survey 1976–95. Obesity Reviews 2002;3:183–90
   PubMedGoogle Scholar
• Ministry of Public Welfare 1997. Available from: URL: http://www.mhlw.go.jp/houdou/0103/h0309–7.html [Accessed 24 October 2003]
   Google Scholar
• Friedrich MJ. Epidemic of obesity expands its spread to developing countries. JAMA 2002;287:1382–6
   PubMed Web of Science ®Google Scholar
• Rocchini AP. Childhood obesity and a diabetes epidemic. N Engl J Med 2002;346:854–5
   PubMed Web of Science ®Google Scholar
• Togashi K, Masuda H, Rankinen T, et al. A 12-year follow-up study of treated obese children in Japan. Int J Obes Relat Metab Disord 2002;26:770–7
   PubMed Web of Science ®Google Scholar
• Shirai K, Shinomiya M, Saito Y, et al. Incidence of childhood obesity over the last 10 years in Japan. Diabetes Res Clin Pract 1990;10(Suppl 1):S65–S70
   PubMedGoogle Scholar
• National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication No. 98–4053; 1998
   Google Scholar
• The Examination Committee of Criteria for ‘Obesity Disease’ in Japan, Japan Society for the Study of Obesity. New criteria for ‘obesity disease’ in Japan. Circ J 2002;66:987–92
   PubMed Web of Science ®Google Scholar
• Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523–9
   PubMed Web of Science ®Google Scholar
• Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97:2099–100
   PubMed Web of Science ®Google Scholar
• Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA 1995;273:461–5
   Google Scholar
• Rimm EB, Stampfer MJ, Giovannucci E, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995;141:1117–27
   PubMed Web of Science ®Google Scholar
• Spataro JA, Dyer AR, Stamler J, et al. Measures of adiposity and coronary heart disease mortality in the Chicago Western Electric Company Study. J Clin Epidemiol 1996;49:849–57
   PubMed Web of Science ®Google Scholar
• Jousilahti P, Tuomilehto J, Varitiainen E, et al. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996;93: 1372–9
   Google Scholar
• Shaper AG, Wannamethee SG, Walker M. Body weight: implications for the prevention of coronary heart disease, stroke, and diabetes mellitus in a cohort study of middle aged men. BMJ 1997;314:1311–7
   Google Scholar
• Harris TB, Launer LJ, Madans J, et al. Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age. BMJ 1997;314:1791–4
   PubMed Web of Science ®Google Scholar
• Tanaka S, Togashi K, Rankinen T, et al. Is adiposity at normal body weight relevant for cardiovascular disease risk? Int J Obes Relat Metab Disord 2002;26:176–83
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tokunaga K, Shimomura I, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994;107:239–46
   PubMed Web of Science ®Google Scholar
• Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery disease mortality in older women. Ann Epidemiol 1993;3:35–41
   Google Scholar
• Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women. JAMA 1993;269:483–7
   PubMed Web of Science ®Google Scholar
• Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J [Clin Res Ed] 1984;289:1257–61
   PubMed Web of Science ®Google Scholar
• Zamboni M, Turcato E, Armellini F, et al. Sagittal abdominal diameter as a practical predictor of visceral fat. Int J Obes Relat Metab Disord 1998;22:655–60
   PubMed Web of Science ®Google Scholar
• Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36:54–9
   PubMed Web of Science ®Google Scholar
• Fujimoto WF, Abbate SL, Kahn SE, et al. The visceral adiposity syndrome in Japanese-American men. Obes Res 1994;2:364–71
   PubMedGoogle Scholar
• Després JP. Dyslipidaemia and obesity. Baillieres Clin Endocrinol Metab 1994;8:629–60
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux S, Lamarche B, et al. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes 1995;19\(Suppl 1):S76–S86
   Google Scholar
• Matsuzawa Y, Shimomura I, Nakamura T, et al. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995;3\(Suppl 2):187S–194S
   Google Scholar
• Garrison RJ, Higgins MW, Kannel WB. Obesity and coronary heart disease. Curr Opin Lipidol 1996;7:199–202
   PubMedGoogle Scholar
• Kanai H, Tokunaga K, Fujioka S, et al. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996;27:125–9
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Nakamura T, Miyaoka K, et al. Visceral fat accumulation contributes to insulin resistance, small-sized low-density lipoprotein, and progression of coronary artery disease in middle-age non-obese Japanese men. Jpn Circ J 2001;65:193–9
   PubMedGoogle Scholar
• Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000;23: 779–85
   Google Scholar
• Matsuzawa Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab Rev 1997;13:3–13
   PubMed Web of Science ®Google Scholar
• Maeda K, Okubo K, Shimomura I, et al. Analysis of an expression profile of genes in the human adipose tissue. Gene 1997;190:227–35
   PubMed Web of Science ®Google Scholar
• Spiegelman BM, Choy L, Hotamisligil GS, et al. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 1993;268:6823–6
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–32
   PubMed Web of Science ®Google Scholar
• Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800–3
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209–14
   PubMed Web of Science ®Google Scholar
• Bluher M, Kratzsch J, Paschke R. Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 2001;24:328–34
   Google Scholar
• Funahashi T, Nakamura T, Shimomura I, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 1999;38:202–6
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999;892:146–54
   Google Scholar
• Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327–32
   PubMed Web of Science ®Google Scholar
• Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18–23
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. The role of TNFa and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621–5
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801–9
   PubMed Web of Science ®Google Scholar
• Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338–42
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473–6
   PubMed Web of Science ®Google Scholar
• Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723–32
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Arita Y, Nishida M, et al. An adiopocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000;32:47–50
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83
   PubMed Web of Science ®Google Scholar
• Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–9
   PubMed Web of Science ®Google Scholar
• Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947–53
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941–6
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930–5
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–12
   PubMed Web of Science ®Google Scholar
• McTernan PG, McTernan CL, Chetty R, et al. Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002;87:2407
   PubMed Web of Science ®Google Scholar
• Engert JC, Vohl MC, Willaims SM, et al. 5’ flanking variants of resistin are associated with obesity. Diabetes 2002;51:1629–34
   PubMed Web of Science ®Google Scholar
• Tornvall P, Olivercrona G, Karpe F, et al. Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1086–93
   PubMed Web of Science ®Google Scholar
• Watanabe H, Miyashita Y, Murano T, et al. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 1999;145:45–50
   PubMed Web of Science ®Google Scholar
• Miyashita Y, Shirai K, Itoh Y, et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 2002;56:181–7
   PubMed Web of Science ®Google Scholar
• Shirai K, Itoh Y, Sasaki H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 1999;46:35–41
   PubMed Web of Science ®Google Scholar
• Totsuka M, Miyashita Y, Ito Y, et al. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 2000;153:175–9
   PubMed Web of Science ®Google Scholar
• Hitsumoto T, Ohsawa H, Uchi T, et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 2000;153:391–6
   PubMed Web of Science ®Google Scholar
• Sacks FM; Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139–43
   Google Scholar
• The UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241–7
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410–8
   PubMed Web of Science ®Google Scholar
• Brochu M, Poehlman ET, Ades PA. Obesity, body fat distribution, and coronary artery disease. J Cardiopulm Rehabil 2000;20:96–108
   Google Scholar
• Flemmer M, Scott J. Mechanism of action of thiazolidinediones. Curr Opin Investig Drugs 2001;2:1564–7
   PubMedGoogle Scholar
• Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes. Heart Dis 2000;2: 326–33
   Google Scholar
• Chakrabarti R, Vikramadithyan RK, Dileepkumar T, et al. Studies on the euglycemic and hyperlipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189. Arzneimittelforschung 1999;49:905–11
   PubMed Web of Science ®Google Scholar
• Vega GL, Grundy SM. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998;81(Suppl):36B–42B
   Google Scholar
• Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002;20:303–28
   Google Scholar
• Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidaemia. Expert Rev Cardiovasc Ther 2003;1:495–505
   PubMedGoogle Scholar
• Stender S, Schuster H, Barter P, et al. Comparing the effects of statins on cholesterol goal achievement and plasma lipids in hypercholesterolaemic patients with and without the metabolic syndrome: results from the MERCURY I trial. Diabetes Metab 2003;29(Suppl):4S138
   Google Scholar
• Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498–511
   PubMed Web of Science ®Google Scholar
• Sprecher DL. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol 2000;86:46L–50L
   Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin–fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155–68
   PubMed Web of Science ®Google Scholar
• Ballantyne CM. Treating mixed dyslipidemias: why and how? Clin Cardiol 2001;24(Suppl 7):II–6–9
   Google Scholar
• Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71–5
   Google Scholar
• Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100:197–204
   PubMed Web of Science ®Google Scholar
• Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57:363–8
   PubMed Web of Science ®Google Scholar
• Bocan TMA, Krause BR, Rosebury WS, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:70–9
   PubMed Web of Science ®Google Scholar